Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tizanidine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Tizanidine (sublingual or oral) | DRUG | - |
| Sublingual Tizanidine HCl | DRUG | - |
Inclusion Criteria: * Male and female patients between the ages of 20-65 * Definitive diagnosis of MS, with Expanded Disability Status Scale (EDSS) less than 6.5 at screening * Has significant spasticity (total Ashworth =\> 6) at screening * Can maintain sleep regimens of at least 5 hours nightly f...
Tizanidine is being studied for use in muscle spasticity and traumatic brain injury. It is a small molecule in development for neurology indications, specifically to address spasticity associated with conditions like multiple sclerosis and chronic traumatic brain injury in pediatric and adult patients.
Tizanidine is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical trials to evaluate the drug's safety and efficacy for neurological conditions.
Tizanidine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness.
Tizanidine has one completed Phase 1 trial, NCT00287157, a pilot proof-of-concept study in children with chronic traumatic brain injury. Another completed trial, NCT00358293, evaluated nighttime dosing in multiple sclerosis patients with significant spasticity. Both were conducted in Israel.
Yes, Tizanidine is the same as sublingual tizanidine. The clinical trials NCT00287157 and NCT00358293 both investigate the sublingual formulation of tizanidine, which is administered under the tongue for potential therapeutic effects.